Rosenberg, Jonathan

Publications

Sort by

Co-Author Network

selected publications

Antibody-Drug Conjugates in Urothelial Carcinomas. Current oncology reports. 2020 Review GET IT
Times cited: 22
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 318
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 134
MCL1 and DEDD Promote Urothelial Carcinoma Progression. Molecular cancer research : MCR. 2019 Academic Article GET IT
Times cited: 2
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2018 Academic Article GET IT
Times cited: 30
Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 130
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. 2018 GET IT
Times cited: 18
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018 Academic Article GET IT
Times cited: 83
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 94
Global Cancer Transcriptome Quantifies Repeat Element Polarization between Immunotherapy Responsive and T Cell Suppressive Classes. Cell reports. 2018 Academic Article GET IT
Times cited: 55
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 343
Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 67
Oncologist use and perception of large panel next-generation tumor sequencing. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 28
Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS medicine. 2017 Academic Article GET IT
Times cited: 209
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2017 Academic Article GET IT
Times cited: 5
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 1423
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 525
Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). European urology. 2016 Academic Article GET IT
Times cited: 49
Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer. 2016 Academic Article GET IT
Times cited: 46
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet (London, England). 2016 Academic Article GET IT
Times cited: 2708
Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature genetics. 2016 Academic Article GET IT
Times cited: 118
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. Cancer. 2015 Academic Article GET IT
Times cited: 25
Improved 5-Factor Prognostic Classification of Patients Receiving Salvage Systemic Therapy for Advanced Urothelial Carcinoma. The Journal of urology. 2015 Academic Article GET IT
Times cited: 42
Genomic Characterization of Upper Tract Urothelial Carcinoma. European urology. 2015 Academic Article GET IT
Times cited: 165
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical genitourinary cancer. 2015 Academic Article GET IT
Times cited: 3
DNA copy number analysis of metastatic urothelial carcinoma with comparison to primary tumors. BMC cancer. 2015 Academic Article GET IT
Times cited: 20
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience. The oncologist. 2015 Academic Article GET IT
Times cited: 36
Novel molecular targets for urothelial carcinoma. Expert opinion on therapeutic targets. 2015 Review GET IT
Times cited: 8
First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients. Hematology/oncology clinics of North America. 2014 Review GET IT
Times cited: 19
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European journal of cancer (Oxford, England : 1990). 2014 Academic Article GET IT
Times cited: 92
Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma. Clinical genitourinary cancer. 2014 Academic Article GET IT
Times cited: 2
Optimal treatment for metastatic bladder cancer. Current oncology reports. 2014 Review GET IT
Times cited: 30
Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer discovery. 2014 Academic Article GET IT
Times cited: 438
Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. European urology. 2014 Academic Article GET IT
Times cited: 110
Synthetic lethality in ATM-deficient RAD50-mutant tumors underlies outlier response to cancer therapy. Cancer discovery. 2014 Academic Article GET IT
Times cited: 97
FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer medicine. 2014 Academic Article GET IT
Times cited: 72
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. 2014 GET IT
Times cited: 231
Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 48
Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014 Academic Article GET IT
Times cited: 2179
A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational new drugs. 2013 Academic Article GET IT
Times cited: 256
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clinical genitourinary cancer. 2013 Review GET IT
Times cited: 26
Molecular targets on the horizon for kidney and urothelial cancer. Nature reviews. Clinical oncology. 2013 Review GET IT
Times cited: 22
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. Journal of the National Cancer Institute. 2013 Academic Article GET IT
Times cited: 73
Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Frontiers in pharmacology. 2013 Academic Article GET IT
Times cited: 14
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. European urology. 2012 Academic Article GET IT
Times cited: 100
Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research. Urologic oncology. 2012 Review GET IT
Times cited: 5
Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Academic Article GET IT
Times cited: 149
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The Lancet. Oncology. 2010 Review GET IT
Times cited: 117
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Letter GET IT
Times cited: 9

more ...

less ...

Background

education and training

M.D., Harvard Medical School 1997
B.S., Duke University 1992

Contact

full name

Jonathan Rosenberg

VIVO Weill Cornell Medical College

Jonathan Rosenberg Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name